• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Children’s National Health System highlights novel approach for cell therapy

February 23, 2017 By Sarah Faulkner

Children’s National Health SystemChildren's National Health System highlights novel approach for cell therapy touted data today from a Phase I dose-ranging study evaluating a cell therapy approach in patients with blood and bone marrow cancers for whom stem cell transplantation hasn’t worked.

Results from the Resolve trial showed that 78% of patients responded to multi-tumor-associated antigen specific lymphocytes (TAA-L) treatment and 44% of patients had complete remission with limited toxicity, according to Children’s National.

“These initial findings suggest that non-genetically engineered antigen-specific lymphocytes can be isolated, expanded and adoptively transferred to severely ill patients with active disease and positively impact tumor regression,” co-principal investigator Dr. Catherine Bollard said in prepared remarks. “We are encouraged by the promise of these data, which support similar efforts to exploit the immunotherapeutic potential of the natural T-cell repertoire.”

The novel cell therapy approach includes introducing a natural T-cell subtype, TAA-L, to high-risk patients with advanced blood cancers, such as acute myeloid leukemia. The study evaluated the safety and efficacy of donor and patient-derived TAA-L to patients with a variety of hematologic cancers in active diesease relapse pre- or post-allogenic hematopoietic stem cell transplantation.

The trial enrolled 10 patients and observed that ex vivo manufactured TAA-L could be successfully isolated and safely infused to patients after disease relapse.

There were no cases of graft-versus-host disease or other autoimmune-mediated toxicity, according to Children’s National, and the researchers did not observe any neurotoxicity associated with the cell therapy.

Last year, Celsion (NSDQ:CLSN) and Children’s National said that the groups are teaming up to tackle refractory solid tumors in pediatric patients using a heat-activated chemotherapy drug and noninvasive ultrasound. The Phase I clinical trial, which launched last November, is the 1st of its kind in the U.S.

Lawrenceville, N.J.-based Celsion’s ThermoDox is a heat-activated liposomal doxorubicin. In combination with MRI, high-intensity focused ultrasound is used to direct sound wave energy and heat the tumor. When the liposomal chemotherapy drug comes into contact with the heated tumor, the liposome changes structure and releases doxorubicin into the tumor.

The study, supported by the National Institutes of Health, is designed to determine the appropriate dose range of ThermoDox for pediatric patients with refractory solid tumors.

Filed Under: Clinical Trials, Featured, Immunotherapy Tagged With: Children's National Health System

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS